Autopsy report · NCT03360721

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer

“\<75% participation”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 8 years before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Castration-Resistant Prostate Carcinoma; Prostate Adenocarcinoma Without Neuroendocrine Differentiation; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8

Interventions

Abiraterone Acetate; Apalutamide; Prednisone

Participants

7

Sites

1

Countries

United States

Trials that died the same way

• ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
  “\<75% participants” (87% match in meaning)
• Vapocoolant Analgesia for Breast Lymphoscintigraphy
  “\<75% accrued participants” (76% match in meaning)
• Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery
  “low participation rate” (72% match in meaning)
• Physiotherapy and Therapeutic Education After Total Knee Arthroplasty.
  “low participation” (70% match in meaning)
• Everolimus in Treating Older Patients With Mantle Cell Lymphoma Previously Treated With First-Line or Second-Line Chemotherapy
  “Lack of participations (8 of 25)” (64% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.